It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 7. Department of pediatrics Graduate School of Medical and Pharmaceutical Sciences, Chiba
- University, Chiba, Japan.
- 8. Department of Cardiovascular Medicine, Saga University, Saga, Japan.
- 9. Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical
- Sciences, Kanagawa, Japan.
- 10. Medical Genome Center, Research Institute, National Center for Geriatrics and Gerontology,
- Obu, Japan.
- 11. Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan.
- 12. Laboratory of Clinical Genome Sequencing, Department of Computational Biology and
- Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo,

Japan.

13. Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences,

Kanagawa, Japan.

- 14. Genome Science Division, Research Center for Advanced Science and Technology, The
- University of Tokyo, Tokyo, Japan.
- 15. Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical
- Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- 16. Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, MA,
- USA.
- 17. Division of Cardiovascular Medicine, Perelman School of Medicine, University of
- Pennsylvania, Philadelphia, PA, USA.
- 18. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 19. Department of Surgery, University of Pennsylvania Perelman School of Medicine,
- Philadelphia, PA, USA.
- 20. Department of Genetics, University of Pennsylvania Perelman School of Medicine,
- Philadelphia, PA, USA.
- 21. Department of Systems Pharmacology and Translational Therapeutics, University of
- Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- 22. Institute of Translational Medicine and Therapeutics, University of Pennsylvania Perelman
- School of Medicine, Philadelphia, PA, USA.
- 23. Veterans Affairs Providence Healthcare System, Providence, RI, USA.
- 24. Brown University, Providence, RI, USA.
- 25. VA Atlanta Health Care System, Decatur, GA, USA.
- 26. Emory University Rollins School of Public Health, Atlanta, GA, USA.
- 27. Department of Epidemiology and Public Health, Graduate School of Medical Sciences,
- Kyushu University.
- 28. Department of Frontier Cardiovascular Science, Graduate School of Medicine, The
- University of Tokyo, Tokyo, Japan.
- 29. International University of Health and Welfare.
-
- Correspondence should be addressed to K.I. (kaoru.ito@riken.jp) and I.K. (komuro-
- tky@umin.ac.jp)

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Abstract:

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Introduction

78 Heart failure (HF) is increasing in prevalence and incidence¹. A previous genome-wide 79 association study (GWAS) of all-cause HF identified 47 risk loci². Considering that GWAS of 80 coronary artery disease (CAD) yielded 175 susceptibility loci³ and GWAS of atrial fibrillation 81 (AF) yielded 150 loci⁴, the number of loci for HF was lower than expected even when using multi-trait analysis of GWAS (MTAG) that jointly analyzes GWAS summary statistics of multiple related traits, boosting statistical power by leveraging information across traits. This is partly because HF is a heterogeneous syndrome resulting from multiple etiologies. GWAS of HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) was 86 performed to address this heterogeneity⁵. This study identified additional susceptibility loci that had not been found in the all-cause HF GWAS. Given this fact, analysis of HF subtypes should be useful to better understand the genetic architecture for HF. On the other hand, since the vast majority of these HF-GWASs have been performed in European populations, the genetic pathophysiology of HF in non-European populations is not well understood. Additionally, it is difficult to apply polygenic risk scores (PRSs) derived from such GWASs to non-European populations.

 Therefore, in the present study, we performed a large-scale Japanese GWAS to explore the genetic architecture of all-cause HF and HF subtypes: HFrEF, HFpEF, and non-ischemic HF (NIHF), followed by a cross-ancestry meta-analysis. Further, we investigated potential causal genes at the identified HF-associated loci by integrating several prioritization methods to characterize the underlying mechanism, clarify the link with cardiomyopathy, and propose gene- drug interactions relevant to HF. We also evaluated the impact of common variants in established cardiomyopathy genes on HF phenotypes and long-term mortality. Subsequently, we

It is made available under a CC-BY-NC-ND 4.0 International license.

- identified a *TTN* common variant, which affected HF severity and mortality rate. Additionally,
- we developed a PRS derived from the cross-ancestry meta-analysis of each HF subtype along
- with HF-related phenotypes and demonstrated the ability of the HF-PRS to predict the early
- onset of HF and stratify the long-term mortality, which may provide evidence for the clinical
- utility of HF-PRS and lay the foundation for the realization of precision medicine in HF.

It is made available under a CC-BY-NC-ND 4.0 International license.

Results

GWAS revealed a Japanese-specific genetic architecture of HF

5.0 \times 10⁻⁶) were additionally detected, increasing the total number of HF-associated signals to 21

126 performed a stepwise conditional analysis, in which three independent variants (locus-wide $P <$

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 Furthermore, related to the HF loci identified in our Japanese GWAS, we assessed nearby genes containing variants classified in ClinVar as having pathogenic evidence for HF-relevant 169 monogenic disorders, knock-out mouse phenotype, and known cardiomyopathy genes¹¹. *NEBL*, located within 500kb of the lead variant rs7075837, was reported to harbor pathogenic variants responsible for primary dilated cardiomyopathy according to the ClinVar database (**Supplementary Table 13**). *NEBL* was also one of the known cardiomyopathy genes (**Supplementary Table 14**), and *Nebl* knock-out mice showed dilatation of the left atrium and

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a CC-BY-NC-ND 4.0 International license.

Genes related to arrhythmia, metabolism, and heart morphology were prioritized in the

cross-ancestry meta-analyses

(**Supplementary Table 28**) and was prioritized by PoPS (**Supplementary Table 29**). Knockout

of *Ednra* showed abnormal heart and aortic morphology (**Supplementary Table 28)** partly

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a CC-BY-NC-ND 4.0 International license.

 To compare the mechanisms of each HF phenotype, we conducted a pathway analysis and found that cellular senescence, cyclin-dependent kinase-related pathway, miRNAs involved in DNA damage responses, signaling events mediated by prolactin, Tie2 mediated signaling, and Notch signaling pathway were enriched in all-cause HF (**Fig. 3** and **Supplementary Table 42**). Notch signaling was also enriched in NIHF. From a clinical perspective, miRNAs involved in

It is made available under a CC-BY-NC-ND 4.0 International license.

We conducted the cell type-specific analysis at single-cell resolution using scDRS⁴⁸ with 308 healthy, dilated cardiomyopathy, and hypertrophic cardiomyopathy datasets⁴⁹. All four HF

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 phenotypes showed significant enrichment for cardiomyocytes (**Supplementary Fig 12b** and **Supplementary Table 45**). Additionally, HFpEF showed enrichment for adipocyte and vascular 311 smooth muscle cells^{50, 51}, suggesting that HFpEF may have additional mechanisms beyond the other HF phenotypes. **Candidate drugs linked to disease susceptibility loci**

315 We curated drugs from DrugBank²⁸ and Therapeutic Target Database^{29, 30} (**Supplementary Fig. 13**) for the prioritized genes from the Japanese GWAS, cross-ancestry meta-analyses, and MTAG. Our analysis supports epidemiological evidence that several medications cause or exacerbate HF. Given that knockout of *CACNA1D*, *EDNRA*, and *CDK6* in mice caused abnormal myocardial fiber physiology, abnormal heart ventricle morphology, and decreased myocardial fiber number, respectively, those inhibitors could worsen HF. Indeed, the previous meta-analysis suggested that dihydropyridine calcium channel blockers (nifedipine) can 322 be a risk for HF^{31} . The EDNRA inhibitor bosentan caused fluid retention in HF patients³². One of the CDK4/6 inhibitors, palbociclib, was associated with worse outcomes in patients who developed atrial fibrillation or $HF³³$. All these outcomes were concordant with our genetic analyses.

Tirzepatide, one of the emerging antidiabetics^{34, 35}, could be a potential drug repositioning candidate through the *GIPR* locus, which had a protective role against HF. As of now, tirzepatide has not been fully evaluated for its effects on cardiovascular outcomes, but at least it did not increase the risk of cardiovascular events³⁶. Currently, a study of tirzepatide in participants with HFpEF (SUMMIT trial) is ongoing (NCT04847557).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

A *TTN* **common variant plays an important role in HF outcomes**

Development of a HF-PRS and its performance

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Impact of HF-PRS on HF phenotypes and outcomes

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Discussion

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 repositioning candidate. By contrast, we genetically proved the detrimental effects of PDE3A and CDK4/6 blockade on HF pathogenesis.

 In these analyses, we found that common variants of the cardiomyopathy genes *TTN*, *NEBL,* and *BAG3* contributed to the development of HF. MTAG additionally identified that common variants of *MYBPC3* were one of the susceptibility loci. Among these, a *TTN* common variant rs1484116 had a significant difference in the frequency and effect between Japanese and European populations. Notably, this common variant stratified individuals who went on to develop HF into those with a high mortality rate. Additionally, while rare truncating variants in the *TTN* gene comprise the most common genetic subtype of dilated cardiomyopathy, accounting for up to 25% of cases⁴¹, we show for the first time that the *TTN* common variant in a non-coding region also causes HF.

 Integrating cross-ancestry GWAS of interest and GWAS of related phenotypes improves 426 predictive performance in CAD^{37} . In our HF-PRS, integrating HFrEF, HFpEF, AF, CAD, and left ventricular mass improved the performance. Moreover, we demonstrated that HF-PRS could predict HF death in subjects who had not yet been diagnosed as having HF.

 Our study has several limitations. First, we did not have other large cohorts for the replication analysis. We did not replicate Japanese-specific HF loci using other East Asian cohorts since there were no other large East Asian biobanks available with enough of these patients. Instead, we assessed these variants with European data, showing the same effect direction. As for cross-ancestry meta-analyses, we did not have a non-overlapping corresponding cohort for all-cause HF and NIHF. Hence, we used European all-cause HF data for the replication of HFrEF and HFpEF cross-ancestry meta-analyses, showing almost the same effect direction. Second, we did not perform quantitative trait-based enrichment analysis (e.g. TWAS

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 and splicing-TWAS) for the Japanese GWAS since there is no available molecular QTL dataset for the East Asian population. Thus, eQTL, sQTL, and other QTL datasets of the East Asian population are required in future research to further clarify the genetic differences between the East Asian and European populations. In conclusion, our large-scale Japanese and cross-ancestry genetic analyses identified 19 new risk loci and provided insights into the distinct and shared genetic architecture of HF between Japanese and Europeans. Multiple prioritization methods allowed us to identify candidate genes involved in the pathogenesis. We also showed that the common variant of *TTN* can be a prognostic marker for HF patients in the Japanese population. Furthermore, analyses of disease prediction and long-term survival demonstrated the clinical utility of our HF-PRS. These data highlight the utility of HF genetics in clinical settings and provide useful evidence for the implementation of genomic medicine.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Online Methods

Study populations

452 We included two cohorts for the Japanese-specific meta-analysis including the BBJ 1st 453 cohort and BBJ $2nd$ cohort from the BioBank Japan Project⁴². Further details on each cohort are described in the **Supplementary Note**. For GWAS quality control, we excluded samples with a call rate < 0.98 and related individuals with pi-hat > 0.2, which is an index of relatedness based on pairwise identity-by descent implemented in PLINK 2.0 (20 Aug 2018 ver.). We then excluded samples with a 458 heterozygosity rate $> +4$ s.d. We performed principal component analysis (PCA) using PLINK 2.0. and excluded outliers from the Japanese cluster. For the case samples in GWAS, we selected individuals with HF diagnosed by a physician based on accepted medical practice criteria. HFrEF was defined as having HF and LVEF < 40%, while HFpEF was defined as having HF and LVEF > 50%. NIHF was defined as having HF without CAD. The demographic features of the case-control cohort are shown in **Supplementary Table 1**. **Genotyping, imputation, and quality control** To construct a population-specific reference panel, we included 7,825 Japanese WGS samples. Each sample was aligned to the human genome assembly GRCh38 and subjected to variant calling individually using the Illumina DRAGEN Bio-IT Platform (versions 3.4.12 and 3.5.7), generating gVCF files. Joint variant calling was subsequently performed with DRAGEN (version 3.6.3), employing default parameters and filtering criteria. Next variant quality control

- (QC) was conducted and variants from the jointly-called dataset were filtered out based on
- 472 several exclusion criteria: 1) the presence of multi-alleles; 2) singleton; 3) missing data rate $>$

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

473 5% ; 4) Hardy-Weinberg Equilibrium (HWE) p-value < 1×10^{-6} . After QC, VCF files were phased 474 on a whole-chromosome basis using SHAPEIT4 (version 4.2)⁴³.

 GWAS subjects were genotyped using the Illumina Human OmniExpress Genotyping BeadChip or a combination of Illumina HumanOmniExpress and HumanExome BeadChips (Illumina, San Diego, CA). For genotype quality control (QC), we excluded variants with (i) 478 SNP call rate < 0.99 , (ii) MAF < 0.01 , and (iii) Hardy–Weinberg equilibrium P value $< 1.0 \times$ 10^{-6} . BBJ 1st and BBJ 2nd cohorts were separately phased using SHAPEIT2 (version r837) and EAGLE2 (version 2.39), respectively. Imputation was then carried out with Minimac4 (version $1.0.0$ ⁴⁴ with a minor adjustment: variant positions in the array data, initially based on hg19, were remapped to GRCh38 using BLAST based on the sequence of flanking sites.

483

484 **GWAS**

485 In the Japanese GWAS, association was performed by logistic regression analysis 486 assuming an additive model with adjustment for age, age², sex, and top 10 principal components 487 (PCs) using REGENIE⁴⁵. We selected variants with Minimac4 imputation quality score of > 0.3 488 and MAF \geq 0.01. The genome-wide significance threshold was defined at $P < 5.0 \times 10^{-8}$. The 489 genomic inflation factor (λ GC) was 1.044, 1.080, 1.050, and 1.083 for all-cause HF, HFrEF, 490 HFpEF, and NIHF, respectively. (**Supplementary Figure. 2a**). Adjacent genome-wide 491 significant SNPs were grouped into one locus if they were within 1 Mb of each other. We 492 defined a locus as follows: (1) extracted genome-wide significant variants ($P < 5.0 \times 10^{-8}$) from 493 the association result, (2) added 500 kb to both sides of these variants, and (3) merged 494 overlapping regions. If the locus did not contain coordinates with previously reported genome-495 wide significant variants (i.e., all variants with $P < 5.0 \times 10^{-8}$ in the previously reported locus),

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

was within ±500kb of variants for the corresponding phenotype in previous all-cause HF,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

statistics to estimate heritability and genetic correlation between polygenic traits while

accounting for sample overlap.

Transcriptome-wide association study

 We performed a transcriptome-wide association study (TWAS) to assess gene-HF associations using FUSION⁴⁸, which estimates the association between predicted gene expression levels and a phenotype of interest using summary statistics and gene expression prediction models. We used precomputed prediction models of gene expression in tissues considered to be relevant for HF with LD reference data in GTEx v8 and the summary statistics of the trans-ancestry HF-GWAS as input. Furthermore, we used the cross-tissue weights generated in GTEx v8 using sparse canonical correlation analysis (sCCA) across 49 tissues available on the FUSION website, including gene expression models for the first three canonical vectors (sCCA1-3), which were shown to capture most of the gene expression signal. Transcriptome-wide significant genes (eGenes) and the corresponding eQTLs were determined using the Bonferroni correction, based on the average number of features (8,036.5 genes) tested across all reference panels and correcting for the four HF phenotypes $(P < 1.55 \times 10^{-6})$. To ensure that the observed associations did not reflect a random correlation between gene expression and non-causal variants associated with stroke, we performed a colocalization analysis on the eGenes to estimate the posterior probability of a shared causal variant between 561 the gene expression and trait association (PP4). eGenes presenting a PP4 \geq 0.75 were considered to be significant.

Splicing-TWAS

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 We performed a splicing-TWAS to assess splicing-HF associations using MetaXcan. We used GTEx v8 MASHR-based models [\(https://github.com/hakyimlab/MetaXcan\)](https://github.com/hakyimlab/MetaXcan). The significant splicing sites were determined using the Bonferroni correction, based on the number of splicing sites multiplied by the four HF phenotypes.

Identifying protein-altering variants

 To identify protein-altering variants among our genome-wide significant associations, we 572 took the sentinel variants and their LD proxies at $r^2 \ge 0.8$ as estimated in the European ancestry subset of 1000 Genomes Project phase 3 and annotated them using the Ensembl VEP. We selected for each sentinel variant any proxies identified as having a 'high' (that is, stop-gain and stop-loss, frameshift insertion and deletion, donor and acceptor splice-site and initiator codon variants) or 'moderate' (that is, missense, in-frame insertion and deletion, splice region) consequence and recorded the gene that the variant disrupts.

Polygenic prioritization of candidate causal genes

 We implemented PoPS, a similarity-based gene prioritization method designed to leverage the full genome-wide signal to nominate causal genes independent of methods utilizing GWAS data proximal to the gene (https://github.com/FinucaneLab/pops.git). Broadly, PoPS leverages polygenic enrichments of gene features including cell-type-specific gene expression, curated biological pathways, and protein-protein interaction networks to train a linear model to compute a PoPS for each gene.

Variants responsible for cardiovascular-relevant monogenic disorders

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 noradrenaline turnover (MP:0021021), cardiac amyloidosis (MP:0021148) along with 612 phenotypes previously used in CAD analysis⁴⁹ (**Supplementary Table 46**). This resulted in mapping from genes to phenotypes in animals (**Supplementary Tables 14, 25,** and **36**). **PRS derivation and performance** First, we divided our dataset into three groups: (i) a discovery group to derive PRS (12,335 cases and 107,333 controls), (ii) a group used for linear combination (1,837 cases and 11,320 controls), (iii) a test group to assess PRS performance (1,837 cases and 11,319 controls), and (iv) a group for the survival analysis (67,991 controls) (**Supplementary Fig. 14**). Next, we used PRS-CS to derive each PRS from Japanese-, European-, American-, African- all-cause HF, European HFrEF, HFpEF, NIHF, AF, CAD, and left ventricular mass. We used LD reference panels constructed using the 1000 Genomes Project phase 3 samples according to each cohort population. Subsequently, we calculated PRSs in the withheld BBJ cohorts for linear combination and conducted logistic regression with L1 regularization and 10-fold cross- validation. Finally, we used the Japanese all-cause HF, European all-cause HF, European HFrEF, European HFpEF, European CAD, European AF, and European left ventricular mass to construct 627 the HF-PRS. The performance of the PRS was measured as (1) Nagelkerke's pseudo- R^2 obtained by modeling age, sex, the top 10 PCs, and normalized PRS and (2) the area under the curve of 629 the receiver operator curve in the same model as Nagelkerke's pseudo R^2 . Using the models

 previously described, we calculated the PRSs and assessed their performance for the independent test cohort.

Association of HF-PRS with age of HF onset

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Data availability

- will be publicly available at the National Bioscience Database Center
- (https://humandbs.dbcls.jp/en/). The GWAS summary statistics for HF (GBMI American:
- https://www.globalbiobankmeta.org/; Kadoorie: https://www.ckbiobank.org/; FinnGen NIHF:
- [https://console.cloud.google.com/storage/browser/_details/finngen-public-data-](https://console.cloud.google.com/storage/browser/_details/finngen-public-data-r9/summary_stats/)
- [r9/summary_stats/,](https://console.cloud.google.com/storage/browser/_details/finngen-public-data-r9/summary_stats/) R9_I9_NONISCHCARDMYOP; UKBB NIHF: https://cvd.hugeamp.org/),
- and cardiac MRI (left ventricle, right ventricle and atrium: [http://kp4cd.org/datasets/mi;](http://kp4cd.org/datasets/mi) left
- atrium: [https://zenodo.org/records/5074929;](https://zenodo.org/records/5074929) left ventricular mass: https://cvd.hugeamp.org/)

traits are publicly available.

Code Availability

 The code used in this study is available on reasonable request to the corresponding authors.

Acknowledgements

We thank the staff of BBJ for their assistance in collecting samples and clinical

information. We thank Naoko Miyagawa, Akio Wada, and Shuji Ito for their technical

assistance. This research was funded by the Japan Agency for Medical Research and

Development (AMED) (JP24bm1423005 to K.I, nos. JP24ek0210164, JP24tm0524004, and

- JP24tm0624002 to K.I., S.N., and I.K., and nos. JP24km0405209 and JP20ek0109487 to K.
- Miyazawa, K. I, S. K., S. N., H. Akazawa, and I. K.), Japan Foundation for Applied Enzymology
- (to N.E), the Japan Society for the Promotion of Science (to N. E. and K. I.), and the Research
- Funding for Longevity Sciences from NCGG (24–15 to K.O. and K.I.). BBJ was supported by

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- the Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports,
- Science, and Technology (MEXT) and AMED under grant numbers JP17km0305002,
- JP17km0305001, and JP24tm0624002.
-

Author Contributions

- N. E., K. I., C. T., Y. K., T. N., and I. K. conceived and designed the study. K. I, C. T., K.
- Matsuda., Y. M., and Y. K. collected and managed the BBJ sample. T. N, Y. M., and Y. K.
- performed the genotyping. N. E, K. Miyazawa, S. K, H. I., R.K., H.Y., F.T., M.F., R.O.
- performed the statistical analyses. N.E, K. I, C. T, S. K., K.T., X.L, K.O., Y. O., T.Y., Y. K.,
- T.N., K.N., H. Akazawa, P.T.E., MG.L., SM.D., BF.V, J.J., and YV.S. contributed to data
- collection, processing, analysis, and interpretation. K. I, C.T., Y K., H. Aburatani, P.T.E. and
- I.K. supervised the study. N.E. and K.I. wrote the manuscript, and many authors have provided valuable edits.
-

Competing interests

The authors declare no competing interests associated with this manuscript.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

References:

- 1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H,
- Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K and Filippatos G.
- Heart failure: preventing disease and death worldwide. *ESC Heart Fail*. 2014;1:4-25.
- 2. Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, Backman JD, Bellomo TR,
- Bone WP, Biddinger KJ, Hui Q, Dikilitas O, Satterfield BA, Yang Y, Morley MP, Bradford Y,
- Burke M, Reza N, Charest B, Regeneron Genetics C, Judy RL, Puckelwartz MJ, Hakonarson H,
- Khan A, Kottyan LC, Kullo I, Luo Y, McNally EM, Rasmussen-Torvik LJ, Day SM, Do R,
- Phillips LS, Ellinor PT, Nadkarni GN, Ritchie MD, Arany Z, Cappola TP, Margulies KB,
- Aragam KG, Haggerty CM, Joseph J, Sun YV, Voight BF and Damrauer SM. Genome-wide
- association and multi-trait analyses characterize the common genetic architecture of heart failure.
- *Nat Commun*. 2022;13:6914.
- 3. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki
- H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa
- K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K,
- Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda
- K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y and Komuro I. Population-
- specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. *Nat Genet*. 2020;52:1169-1177.
- 4. Miyazawa K, Ito K, Ito M, Zou Z, Kubota M, Nomura S, Matsunaga H, Koyama S, Ieki
- H, Akiyama M, Koike Y, Kurosawa R, Yoshida H, Ozaki K, Onouchi Y, BioBank Japan P,
- Takahashi A, Matsuda K, Murakami Y, Aburatani H, Kubo M, Momozawa Y, Terao C, Oki S,
- Akazawa H, Kamatani Y and Komuro I. Cross-ancestry genome-wide analysis of atrial

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

fibrillation unveils disease biology and enables cardioembolic risk prediction. *Nat Genet*.

2023;55:187-197.

- 5. Joseph J, Liu C, Hui Q, Aragam K, Wang Z, Charest B, Huffman JE, Keaton JM,
- Edwards TL, Demissie S, Djousse L, Casas JP, Gaziano JM, Cho K, Wilson PWF, Phillips LS,
- Program VAMV, O'Donnell CJ and Sun YV. Genetic architecture of heart failure with preserved
- versus reduced ejection fraction. *Nat Commun*. 2022;13:7753.
- 6. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma
- T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, Suzuki K, Obara W, Yamaji K, Takahashi
- K, Asai S, Takahashi Y, Suzuki T, Shinozaki N, Yamaguchi H, Minami S, Murayama S,
- Yoshimori K, Nagayama S, Obata D, Higashiyama M, Masumoto A, Koretsune Y, FinnGen, Ito
- K, Terao C, Yamauchi T, Komuro I, Kadowaki T, Tamiya G, Yamamoto M, Nakamura Y, Kubo
- M, Murakami Y, Yamamoto K, Kamatani Y, Palotie A, Rivas MA, Daly MJ, Matsuda K and
- Okada Y. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet*. 2021;53:1415-1424.
- 7. Gorska AA, Sandmann C, Riechert E, Hofmann C, Malovrh E, Varma E, Kmietczyk V,
- Olschlager J, Jurgensen L, Kamuf-Schenk V, Stroh C, Furkel J, Konstandin MH, Sticht C,
- Boileau E, Dieterich C, Frey N, Katus HA, Doroudgar S and Volkers M. Muscle-specific Cand2
- is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling. *EMBO Rep*. 2021;22:e52170.
- 8. de Leeuw CA, Mooij JM, Heskes T and Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol*. 2015;11:e1004219.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 15. Motta M, Fasano G, Gredy S, Brinkmann J, Bonnard AA, Simsek-Kiper PO, Gulec EY,
- Essaddam L, Utine GE, Guarnetti Prandi I, Venditti M, Pantaleoni F, Radio FC, Ciolfi A, Petrini
- S, Consoli F, Vignal C, Hepbasli D, Ullrich M, de Boer E, Vissers L, Gritli S, Rossi C, De Luca
- A, Ben Becher S, Gelb BD, Dallapiccola B, Lauri A, Chillemi G, Schuh K, Cave H, Zenker M
- and Tartaglia M. SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype.
- *Am J Hum Genet*. 2021;108:2112-2129.
- 16. Walters RG, Millwood IY, Lin K, Schmidt Valle D, McDonnell P, Hacker A, Avery D,
- Edris A, Fry H, Cai N, Kretzschmar WW, Ansari MA, Lyons PA, Collins R, Donnelly P, Hill M,
- Peto R, Shen H, Jin X, Nie C, Xu X, Guo Y, Yu C, Lv J, Clarke RJ, Li L, Chen Z and China
- Kadoorie Biobank Collaborative G. Genotyping and population characteristics of the China
- Kadoorie Biobank. *Cell Genom*. 2023;3:100361.
- 17. Zhou W, Kanai M, Wu KH, Rasheed H, Tsuo K, Hirbo JB, Wang Y, Bhattacharya A,
- Zhao H, Namba S, Surakka I, Wolford BN, Lo Faro V, Lopera-Maya EA, Lall K, Fave MJ,
- Partanen JJ, Chapman SB, Karjalainen J, Kurki M, Maasha M, Brumpton BM, Chavan S, Chen
- TT, Daya M, Ding Y, Feng YA, Guare LA, Gignoux CR, Graham SE, Hornsby WE, Ingold N,
- Ismail SI, Johnson R, Laisk T, Lin K, Lv J, Millwood IY, Moreno-Grau S, Nam K, Palta P,
- Pandit A, Preuss MH, Saad C, Setia-Verma S, Thorsteinsdottir U, Uzunovic J, Verma A,
- Zawistowski M, Zhong X, Afifi N, Al-Dabhani KM, Al Thani A, Bradford Y, Campbell A,
- Crooks K, de Bock GH, Damrauer SM, Douville NJ, Finer S, Fritsche LG, Fthenou E, Gonzalez-
- Arroyo G, Griffiths CJ, Guo Y, Hunt KA, Ioannidis A, Jansonius NM, Konuma T, Lee MTM,
- Lopez-Pineda A, Matsuda Y, Marioni RE, Moatamed B, Nava-Aguilar MA, Numakura K, Patil
- S, Rafaels N, Richmond A, Rojas-Munoz A, Shortt JA, Straub P, Tao R, Vanderwerff B,
- Vernekar M, Veturi Y, Barnes KC, Boezen M, Chen Z, Chen CY, Cho J, Smith GD, Finucane

- HK, Franke L, Gamazon ER, Ganna A, Gaunt TR, Ge T, Huang H, Huffman J, Katsanis N,
- Koskela JT, Lajonchere C, Law MH, Li L, Lindgren CM, Loos RJF, MacGregor S, Matsuda K,
- Olsen CM, Porteous DJ, Shavit JA, Snieder H, Takano T, Trembath RC, Vonk JM, Whiteman
- DC, Wicks SJ, Wijmenga C, Wright J, Zheng J, Zhou X, Awadalla P, Boehnke M, Bustamante
- CD, Cox NJ, Fatumo S, Geschwind DH, Hayward C, Hveem K, Kenny EE, Lee S, Lin YF,
- Mbarek H, Magi R, Martin HC, Medland SE, Okada Y, Palotie AV, Pasaniuc B, Rader DJ,
- Ritchie MD, Sanna S, Smoller JW, Stefansson K, van Heel DA, Walters RG, Zollner S, Biobank
- of the A, Biobank Japan P, BioMe, BioVu, CanPath Ontario Health S, China Kadoorie Biobank
- Collaborative G, Colorado Center for Personalized M, de CG, Estonian B, FinnGen, Generation
- S, Genes, Health Research T, LifeLines, Mass General Brigham B, Michigan Genomics I,
- National Biobank of K, Penn Medicine B, Qatar B, Sun QS, Health S, Taiwan B, Study H,
- Initiative UACH, Uganda Genome R, Biobank UK, Martin AR, Willer CJ, Daly MJ and Neale
- BM. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease.
- *Cell Genom*. 2022;2:100192.
- 18. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi SH, Shoemaker MB, Haas
- ME, Weng LC, Lindsay ME, Smith JG, Newton-Cheh C, Roden DM, London B, Investigators
- G, Wells QS, Ellinor PT, Kathiresan S, Lubitz SA and Genetic Risk Assessment of Defibrillator
- Events I. Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic
- Discovery. *Circulation*. 2019;139:489-501.
- 19. Asai R, Kurihara Y, Fujisawa K, Sato T, Kawamura Y, Kokubo H, Tonami K, Nishiyama
- K, Uchijima Y, Miyagawa-Tomita S and Kurihara H. Endothelin receptor type A expression
- defines a distinct cardiac subdomain within the heart field and is later implicated in chamber
- myocardium formation. *Development*. 2010;137:3823-33.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Lau ES, Al'Aref SJ, Asnani A, Sharma G and Mehta JL. Prolactin Inhibition in Peripartum
- Cardiomyopathy: Systematic Review and Meta-analysis. *Curr Probl Cardiol*. 2023;48:101461.
- 26. Qu X, Harmelink C and Baldwin HS. Tie2 regulates endocardial sprouting and
- myocardial trabeculation. *JCI Insight*. 2019;5.
- 27. MacGrogan D, Munch J and de la Pompa JL. Notch and interacting signalling pathways
- in cardiac development, disease, and regeneration. *Nat Rev Cardiol*. 2018;15:685-704.
- 28. Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin
- NEL, Strawbridge SA, Garcia-Patino M, Kruger R, Sivakumaran A, Sanford S, Doshi R,
- Khetarpal N, Fatokun O, Doucet D, Zubkowski A, Rayat DY, Jackson H, Harford K, Anjum A,
- Zakir M, Wang F, Tian S, Lee B, Liigand J, Peters H, Wang RQR, Nguyen T, So D, Sharp M, da
- Silva R, Gabriel C, Scantlebury J, Jasinski M, Ackerman D, Jewison T, Sajed T, Gautam V and
- Wishart DS. DrugBank 6.0: the DrugBank Knowledgebase for 2024. *Nucleic Acids Res*.
- 2024;52:D1265-D1275.
- 29. Chen X, Ji ZL and Chen YZ. TTD: Therapeutic Target Database. *Nucleic Acids Res*. 2002;30:412-5.
- 30. Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y and Chen Y. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. *Nucleic Acids Res*. 2022;50:D1398-D1407.
- 31. Chaugai S, Sherpa LY, Sepehry AA, Kerman SRJ and Arima H. Effects of Long- and
- Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic
- Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials. *J*
- *Cardiovasc Pharmacol Ther*. 2018;23:433-445.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Khera AV. A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. *Nat Med*. 2023;29:1793-1803.
- 38. Wang Y, Namba S, Lopera E, Kerminen S, Tsuo K, Lall K, Kanai M, Zhou W, Wu KH,
- Fave MJ, Bhatta L, Awadalla P, Brumpton B, Deelen P, Hveem K, Lo Faro V, Magi R,
- Murakami Y, Sanna S, Smoller JW, Uzunovic J, Wolford BN, Global Biobank Meta-analysis I,
- Willer C, Gamazon ER, Cox NJ, Surakka I, Okada Y, Martin AR and Hirbo J. Global Biobank
- analyses provide lessons for developing polygenic risk scores across diverse cohorts. *Cell*
- *Genom*. 2023;3:100241.
- 39. Kanemaru K, Cranley J, Muraro D, Miranda AMA, Ho SY, Wilbrey-Clark A, Patrick
- Pett J, Polanski K, Richardson L, Litvinukova M, Kumasaka N, Qin Y, Jablonska Z, Semprich
- CI, Mach L, Dabrowska M, Richoz N, Bolt L, Mamanova L, Kapuge R, Barnett SN, Perera S,
- Talavera-Lopez C, Mulas I, Mahbubani KT, Tuck L, Wang L, Huang MM, Prete M, Pritchard S,
- 881 Dark J, Saeb-Parsy K, Patel M, Clatworthy MR, Hubner N, Chowdhury RA, Noseda M and
- Teichmann SA. Spatially resolved multiomics of human cardiac niches. *Nature*. 2023;619:801-
- 810.
- 40. Baig SM, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G, Ali A, Ahmad I,
- Sinnegger-Brauns MJ, Brandt N, Engel J, Mangoni ME, Farooq M, Khan HU, Nurnberg P,
- Striessnig J and Bolz HJ. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy
- with bradycardia and congenital deafness. *Nat Neurosci*. 2011;14:77-84.
- 41. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L,
- DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ,
- Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE,

- Truncations of titin causing dilated cardiomyopathy. *N Engl J Med*. 2012;366:619-28.
- 42. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T,
- Tamakoshi A, Yamagata Z, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H,
- Tanaka T, Ohnishi Y, Nakamura Y, BioBank Japan Cooperative Hospital G and Kubo M.
- Overview of the BioBank Japan Project: Study design and profile. *J Epidemiol*. 2017;27:S2-S8.
- 43. Delaneau O, Zagury JF, Robinson MR, Marchini JL and Dermitzakis ET. Accurate,
- scalable and integrative haplotype estimation. *Nat Commun*. 2019;10:5436.
- 44. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy
- S, McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG, Swaroop A, Scott LJ, Cucca
- F, Kronenberg F, Boehnke M, Abecasis GR and Fuchsberger C. Next-generation genotype
- imputation service and methods. *Nat Genet*. 2016;48:1284-1287.
- 45. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, Benner C,
- O'Dushlaine C, Barber M, Boutkov B, Habegger L, Ferreira M, Baras A, Reid J, Abecasis G,
- Maxwell E and Marchini J. Computationally efficient whole-genome regression for quantitative
- and binary traits. *Nat Genet*. 2021;53:1097-1103.
- 46. Zhang L, Ono Y, Qiao Q and Nagai T. Trends in heart failure prevalence in Japan 2014-
- 2019: a report from healthcare administration databases. *ESC Heart Fail*. 2023;10:1996-2009.
- 47. Ide T, Kaku H, Matsushima S, Tohyama T, Enzan N, Funakoshi K, Sumita Y, Nakai M,
- Nishimura K, Miyamoto Y, Tsuchihashi-Makaya M, Hatano M, Komuro I, Tsutsui H and
- Investigators J. Clinical Characteristics and Outcomes of Hospitalized Patients With Heart
- Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure
- (JROADHF). *Circ J*. 2021;85:1438-1450.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Figures

 Fig. 1 | Overview of the study design. Flowchart of the study, which encompasses the Japanese GWAS with the BioBank Japan, a trans-ancestry meta-analysis with large-scale European and other population GWAS followed by the downstream analysis. GWAS, genome wide association study; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NIHF; non-ischemic heart failure; TWAS, transcriptome-wide association study.

 Fig. 2 | Prioritized genes. (a) The odds ratios for HF development of the independent signals in the Japanese GWAS, cross-ancestry meta-analysis, and MTAG. The color of each point indicates 947 the corresponding HF phenotype. The size of each point indicates $-log_{10}(P value)$. The shape of each point indicates the methods of analysis. The marker inside each point indicates novelty status. **(b)** Prioritized genes for each HF phenotype according to the types of analyses. *CACNA1D* was prioritized in both BBJ and cross-ancestry meta-analysis and is shown in the "Meta-analysis" row. BBJ, BioBank Japan; HF, heart failure; HFpEF, heart failure with

- preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; Meta, meta-
- analysis; MTAG, multi-trait analysis of genome-wide association study; NIHF, non-ischemic
- heart failure.

It is made available under a CC-BY-NC-ND 4.0 International license.

955

Database \bullet GO O KEGG O PIO REACTOME ^O **WP**

956 **Fig. 3 | Pathway analysis for each HF phenotype.** Enriched terms (FDR < 0.05) for each HF

957 phenotype from GO, KEGG, PI, Reactome, and WP. Up to the top 20 enriched terms in each HF

- 958 phenotype gene set are labeled. The color of the dots indicates the pathway. There was no
- 959 enriched pathway for HFpEF. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and
- 960 Genomes; PI, Pathway Interaction database; WP, Wiki Pathways.

 Fig. 4 | Effects of common variants in cardiomyopathy genes on left ventricular function and long-term HF mortality. (a) Minor allele frequency of lead SNPs in cardiomyopathy genes for East Asian and European populations according to gnomAD. **(b)** Effect size comparison of rs148116 (*TTN*) between BBJ and European for HFrEF. **(c)** Effects of lead variants in cardiomyopathy genes on LVEF in BBJ cohorts (left panel) and UKBB cohorts (right panel). Data are presented as estimated coefficients and their 95% confidence interval (CI). The shape of the points in c and d indicates the HF subtypes. Red points in c and d indicate statistically

- significant effects. HF, heart failure; NIHF, non-ischemic heart failure. **(d)** Effects of lead
- variants in cardiomyopathy genes for HF mortality among HF patients (indicated as circles, ICD-
- 10 I50, 326 deaths among 8,481 individuals) and non-HF individuals (indicated as squares, ICD-
- 10 I50, 749 deaths among 121,070 individuals). **(e)** Cumulative incidence curve for HF death
- according to carriers of rs1484116 (*TTN*) in HF patients.

It is made available under a CC-BY-NC-ND 4.0 International license.

975 **Fig. 5 | Performance and clinical impact of the HF-PRS. (a)** Each point indicates

976 Nagelkerke's pseudo R^2 for all-cause HF case-control status in the Japanese independent cohort

977 (1,837 cases and 11,319 controls). PRS-derivation cohorts are indicated on the x-axis. **(b)**

978 Association between HF-PRS and onset age of HF. The onset age of HF in individuals with data

979 available ($n = 10,810$) is shown based on the HF-PRS tertiles. The number of individuals in each

980 tertile is 3,603 to 3,604. The center line of the box plot indicates the median, the bounds

981 represent the first and third quartile, and the whiskers reach to 1.5 times the interquartile range.

- 982 **(c)** Kaplan-Meier estimates of cumulative events from cardiovascular mortality (left) and HF
- 983 death (right) are shown with a band of 95%CI. Individuals are classified into high (top tertile),
- 984 intermediate (middle tertile), and low PRS (bottom tertile). P values were calculated for PRS by
- 985 Cox proportional hazard analysis and the significance was set at $P = 8.3 \times 10^{-3}$ (0.05/6).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Supplementary Notes

1. The SNP heritability and the liability-scale heritability

- The proportion of the variation in HF phenotypes (the single nucleotide polymorphism (SNP)
- 51 heritability; h^2) was estimated to be 1.5% (standard error of the mean [s.e.m.] 0.3%) for all-cause

HF, 1.5% (0.3%) for HFrEF, 0.5% (0.3%) for HFpEF, and 1.1% (0.3%) for NIHF using linkage

53 disequilibrium (LD)-score regression (LDSC). The liability-scale h^2 was estimated at 4.8%

(s.e.m. 1.0%) for all-cause HF, 12.6% (2.9%) for HFrEF, 2.8% (1.7%) for HFpEF, and 3.1%

(1.0%) for NIHF, suggesting the heterogeneous heritability in each HF phenotype.

2. Replication of previously identified HF risk loci

58 We assessed the 47 independent variants previously reported from all-cause HF GWAS¹, 13

59 variants from HFrEF GWAS, one variant from HFpEF GWAS², and one variant from NIHF³ in

our Japanese GWAS (BBJ). Out of 47 variants identified in the previous all-cause HF GWAS,

34 variants or variants tagged with the lead variant existed in BBJ, 28 had the same effect

direction, and 18 were nominally significant (*P* < 0.05; **Supplementary Fig. 2, Supplementary**

Table 3). Out of 13 variants identified in the European HFrEF GWAS, 11 existed in BBJ, 10 had

the same effect direction, and 3 were nominally significant. The lead variant identified in the

European HFpEF GWAS had the same direction and was nominally significant in BBJ, and the

lead or tagged variant identified in the European NIHF GWAS did not exist in BBJ.

3. Internal and external replication for novel loci found in BBJ GWAS

We sought to replicate the HF-risk loci that reached genome-wide significance in individual

GWAS cohorts. The effect size, direction (**Supplementary Fig. 3a**), and allele frequency of the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

5. Internal and external replication of cross-ancestry meta-analyses results

 The effect size and direction of the identified lead variants (**Supplementary Fig. 7b**) were concordant in East Asians and Europeans for all HF phenotypes (Pearson's correlation: all- cause HF 0.898; HFrEF 0.864; NIHF 0.983) except for HFpEF, for which Pearson's correlation 98 could not be calculated with significant loci $<$ 3. To replicate lead variants of HFrEF and HFpEF using independent datasets, these were assessed with European all-cause HF GWAS since there were no other available HFrEF/HFpEF GWAS datasets. As for all-cause HF and NIHF, there was no dataset for external replication. Effect sizes were generally concordant with Pearson's correlation of 0.817 in HFrEF (**Supplementary Figure 7d and e**). The effect direction was also concordant in all of the three novel loci (**Supplementary Table 21**). As for HFpEF, both significant variants were known HF- related variants.

6. Prioritization of rs10851802 in the cross-ancestry meta-analyses

 Among novel loci, we could not prioritize a gene for rs10851802. rs10851802 is linked to *GLCE* 109 according to the Open Targets database. rs10851802 was associated with rs2415040 ($r^2 = 0.548$), 110 which was a variant for lean mass⁴. Lean mass is associated with incident $HF⁵$. Although we could not prioritize a gene in this locus, this evidence suggests that this locus was one of the disease susceptibility loci. Further investigations were warranted to identify the candidate gene in this locus.

7. Prioritized genes in MTAG

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Supplementary methods

138 **Cohort characteristics for BBJ** 1st cohort and BBJ^{2nd cohort}

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 We searched medications linked to prioritized genes using DrugBank and the Therapeutic Target Database. Among medications with the same pharmacological actions, we chose a representative

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- one manually. The role of prioritized genes (e.g. protective or detrimental against HF) was
- determined based on (1) knockout mice phenotyping or (2) the direction of TWAS Z-score if
- knockout mice phenotyping was not reported to be associated with HF.
-

miRNA enrichment analysis

- The overall polygenic contribution of miRNA–target gene network to the traits through the
- 168 issue-naïve approach was estimated using MIGWAS software with default settings¹². The
- significance threshold was set at 0.0125 based on the number of HF phenotypes (0.05/4).
- Candidate miRNA-gene pairs were estimated by MIGWAS with a significance threshold set at
- FDR < 0.05 for miRNA and genes.
-

Heritability enrichment with scDRS

174 To determine which cell types in hearts were enriched for HF GWAS, we used scDRS $(v.1.0.2)^{13}$ 175 with default settings. We used MAGMA v.1.10¹⁴ to map single-nucleotide polymorphisms to genes (GRCh37 genome build from the 1000 Genomes Project) using an annotation window of 0 kb. We used the resulting annotations and GWAS summary statistics to calculate each gene's MAGMA z score (association with a given trait). The 1,000 disease genes used for scDRS were chosen and weighted based on their top MAGMA z scores. To determine trait association at the annotated cell type resolution, we used the z scores computed from scDRS's downstream Monte Carlo test. These Monte Carlo z scores were converted to theoretical P values using a one-sided 182 test under a normal distribution. The significance threshold was set at $P < 2.4 \times 10^{-3}$ based on Bonferroni correction (0.05/21 based on the number of cell types).

It is made available under a CC-BY-NC-ND 4.0 International license.

Supplementary Figures

 Supplementary Fig. 1 | Results of Japanese GWAS. (a) Sample overlap between each HF phenotype in Japanese GWAS. **(b)** Miami plot for four HF phenotypes. -log10(*P* value) on the *y*- axis are shown against the genomic positions (hg19) on the *x*-axis. Association signals that 190 reached a genome-wide significance level $(P < 5 \times 10^{-8})$ are shown in red if new loci and in blue if previously reported only in MTAG but not in GWAS. **(c)** QQ plot for each HF phenotype in Japanese GWAS. Two-sided *P* values were calculated using a logistic regression model. GWAS, genome-wide association study; HF, heart failure; MTAG, multi-trait analysis of GWAS.

It is made available under a CC-BY-NC-ND 4.0 International license.

Supplementary Fig. 2 | Validation of previously identified HF loci in BBJ. Comparison of

 allelic effects **(a)** and allele frequency **(b)** between the previous GWAS and BBJ. Effect size with its 95%CI or allele frequency of previous GWAS are shown in the *x*-axis, and those of BBJ are

shown in the *y-*axis.

201 **Supplementary Fig. 3 | Comparison of allele frequencies and allelic effects identified in** 202 **Japanese GWAS.** (**a** and **b**) Comparison of allelic effects **(a)** and allele frequency **(b)** between 203 BBJ 1st and BBJ 2nd. Effect size with its 95%CI or allele frequency of BBJ 1st GWAS are shown 204 in the *x*-axis, and those of BBJ 2^{nd} are shown in the *y*-axis. (c and **d**) Comparison of allelic 205 effects (**c**) and allele frequencies (**d**) between our Japanese GWAS (BBJ) and European GWAS. 206 Effect size and its 95%CI, or allele frequencies of BBJ are shown in the *x*-axis, and those of

- European GWAS are shown in the *y*-axis. Points are shown in red if new loci and in blue if
- previously reported only in MTAG but not in GWAS. CI, confidence interval; GWAS, genome-
- wide association study; HF, heart failure; MTAG, multi-trait analysis of GWAS; QQ, quantile-
- quantile.
-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- in GTEx database. **(d)** Manhattan plots of H-MAGMA using aorta or adrenal gland Hi-C
- datasets. -log10(FDR) on the *y*-axis are shown against the genomic positions (hg19) on the *x*-axis.
- Genes that have not been identified in previous TWAS, proteome-wide MR, or gene analysis are
- shown in red. ** indicates novel loci, and * indicates loci previously reported only in MTAG and
- not in GWAS. eQTL, expression quantitative trait loci; GWAS, genome-wide association study;
- HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure
- with reduced ejection fraction; H-MAGMA, Hi-C coupled MAGMA; LAA, left atrial
- appendage; MTAG, multi-trait analysis of GWAS; NIHF; non-ischemic heart failure; sQTL,
- splicing quantitative trait loci.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Supplementary Fig. 5 | Phenogram of genome-wide significant loci for HF and its subtypes.

Indicated gene names are the prioritized gene when one gene is prioritized by our methods, the

nearest gene when multiple genes are prioritized equally, and the blank when none is prioritized

and nearest gene is RNA gene. The shapes indicate HF subtypes; circles, all-cause HF;

rectangles, HFrEF; triangles, HFpEF; and diamonds, non-ischemic HF. Colors indicate HF and

its subtypes; red, BioBank Japan (BBJ); gray, European (EUR); light green, trans-ancestry meta-

analysis (META); and black, multi-trait analysis of GWAS (MTAG). Cytobands and annotations

are based on GRCh37/hg19. Gene names were annotated if prioritized by at least 3 methods.

 Supplementary Fig. 6 | Results of the cross-ancestry meta-analysis. Miami plot of trans- ancestry meta-analysis. -log10(*P* value) on the *y*-axis is shown against the genomic positions 243 (hg19) on the *x*-axis. Association signals that reached a genome-wide significance level ($P < 5 \times$ 10^{-8}) are shown in red if new loci and in blue if previously reported only in MTAG but not in GWAS. GWAS, genome-wide association study; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; MTAG, multi-trait analysis of GWAS.

It is made available under a CC-BY-NC-ND 4.0 International license.

 Supplementary Fig. 7 | QQ plot and comparison of allele frequencies and allelic effects identified in the cross-ancestry meta-analysis. (a) QQ plot for each HF phenotype in the cross- ancestry meta-analysis. Two-sided *P* values were calculated using a logistic regression model. **(b** and **c)** Comparison of allelic effects **(b)** and allele frequency **(c)** between East Asian GWAS and European GWAS. Effect size with its 95%CI or allele frequency of East Asian (for all-cause HF) or BBJ (other HF phenotypes) GWAS are shown in the *x-*axis, and those of European are shown in the *y-*axis. **(d** and **e)** Comparison of allelic effects between the cross-ancestry meta-analysis

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- (HFrEF or HFpEF) and non-overlapping European GWAS (GBMI European all-cause HF).
- Effect size with its 95%CI (**d**) or allele frequencies (**e**) of the cross-ancestry meta-analysis are
- shown in the *x*-axis, and those of European GWAS are shown in the *y-*axis. Points are shown in
- red if new loci and in blue if previously reported only in MTAG but not in GWAS. CI,
- confidence interval; GWAS, genome-wide association study; HF, heart failure; HFrEF, heart
- failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction;
- MTAG, multi-trait analysis of GWAS; QQ, quantile-quantile.

It is made available under a CC-BY-NC-ND 4.0 International license.

 Supplementary Fig. 8 | Downstream analysis of the cross-ancestry meta-analysis. (a) Heatmap of the TWAS of HF (all-cause HF and HF subtypes) showing transcriptome-wide significant associations with supporting evidence from colocalization. Colored squares TWAS 268 significant associations based on two-sided P values after multiple testing corrections ($P <$

1.55 × 10−6). * indicate PP4 0.75-0.8, ** 0.8-0.9, *** 0.9-1.0. **(b)** Heatmap of the Splicing-

TWAS HF showing splicing-wide significant associations. Colored squares splicing-TWAS

significant associations based on two-sided *P* values after multiple testing corrections. Genes are

It is made available under a CC-BY-NC-ND 4.0 International license.

- presented on the *x*-axis, and tissue types are on the *y*-axis in both **(a)** and **(b)**. **(c)** Manhattan plots
- of MAGMA for all-cause HF, HFrEF, and non-ischemic heart failure. -log10(FDR) on the *y*-axis
- are shown against the genomic positions (hg19) on the *x*-axis. Genes that have not been
- identified in previous TWAS, proteome-wide MR, or gene analysis are shown in red. HF, heart
- failure; TWAS, transcriptome-wide association studies.
It is made available under a CC-BY-NC-ND 4.0 International license.

 Supplementary Fig. 9 | Results of multi-trait analysis of GWAS. (a) Genetic correlation between HF and cardiac MRI-derived parameters. Significant genetic correlations (P <0.05) are marked with an asterisk. Two-sided *P* values were calculated using linkage disequilibrium score regression. **(b)** Miami plot of MTAG. -log10(*P* value) on the *y*-axis are shown against the genomic positions (hg19) on the *x*-axis. Association signals that reached a genome-wide 284 significance level $(P < 5 \times 10^{-8})$ are shown in red if new loci. **(c)** QQ plot for each HF phenotype in MTAG. GWAS, genome-wide association study; HF, heart failure; HFpEF, heart failure with

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MTAG, multi-
- trait analysis of GWAS; NIHF, non-ischemic heart failure; QQ, quantile-quantile.

It is made available under a CC-BY-NC-ND 4.0 International license.

It is made available under a CC-BY-NC-ND 4.0 International license.

- on the *y*-axis in both **(a)** and **(b)**. **(c and d)** Manhattan plots of MAGMA for all-cause HF or non-
- ischemic heart failure **(c)**, and H-MAGMA using aorta Hi-C datasets in all-cause HF**(d)**. -
- log10(FDR) on the *y*-axis are shown against the genomic positions (hg19) on the *x*-axis. Genes
- that have not been identified in previous TWAS, proteome-wide MR, or gene analysis are shown
- in red. HF, heart failure; TWAS, transcriptome-wide association studies.

It is made available under a CC-BY-NC-ND 4.0 International license.

- **Supplementary Fig. 11 | Benn diagram for genes identified by each analysis.** BBJ, BioBank
- Japan; EUR, European; META, meta-analysis; MTAG, multi-trait analysis of GWAS.

It is made available under a CC-BY-NC-ND 4.0 International license.

Supplementary Fig. 12 | miRNA enrichment analysis and single-cell enrichment analysis.

(a) MIGWAS results of the four HF phenotypes. The overall contribution of miRNA-target gene

- network to the traits through the tissue-naïve approach. An enrichment signal is shown by -
- log10(*P*MIGWAS). **(b)** Heatmaps depicting each cell type-disease association for HF phenotypes.
- Heatmap colors denote uncorrected *P* value of cell-type-disease association evaluated using
- scDRS. Only significant associations are shown.

It is made available under a CC-BY-NC-ND 4.0 International license.

Supplementary Fig. 13 | Candidate drugs linked to disease susceptibility loci for HF. Dark

blue indicates HF subtypes; orange gene; purple medications; and brown diseases.

It is made available under a CC-BY-NC-ND 4.0 International license.

Supplementary Fig. 14 | Analytical scheme for PRS development. Schematic representation

for derivation, cross-validation, performance testing of HF-PRS in the independent test cohort,

and survival analysis for HF-PRS.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

325 **Supplementary Fig. 15 | PRS performance. (a)** Pairwise comparison of PRS performance. 326 Distribution of the pairwise difference of Nagelkerke's pseudo- R^2 (Δ pseudo- R^2 : Pseudo R^2 score 327 Y – Pseudo R²_{Score} X, X, and Y are found at the axis) between each pair of PRS models. The 328 distributions were obtained by bootstrapping 5.0×10^4 times. Two-sided bootstrap *P* values were 329 calculated by counting the number of Δ pseudo-R² \leq 0 or Δ pseudo-R² $>$ 0 and then multiplying 330 the lower value by the minimum estimated *P* value $(2 * 1 / (5.0 \times 10^4) = 4 \times 10^{-5}$: two-sided). 331 The significance was set at P = 5.0 × 10−3 (0.05/10). **(b)** PRS distribution and HF prevalence. 332 Prevalence of HF based on the HF-PRS deciles in each combination of GWAS. The number of 333 individuals in each decile is 2,631-2,632. Data are presented as medians and 95% CI. PRS, 334 polygenic risk score; CI, confidence interval.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

335 **Members of participating consortia**

336 **The Biobank Japan Project**

- 337 Koichi Matsuda^{1,2}, Takayuki Morisaki^{2,3}, Yukinori Okada⁴, Yoichiro Kamatani⁵, Kaori Muto⁶,
- 338 Akiko Nagai⁶, Yoji Sagiya², Natsuhiko Kumasaka⁷, Yoichi Furukawa⁸, Yuji Yamanashi³,
- 339 Yoshinori Murakami³, Yusuke Nakamura³, Wataru Obara⁹, Ken Yamaji¹⁰, Kazuhisa
- 340 Takahashi¹¹, Satoshi Asai^{12,13}, Yasuo Takahashi¹³, Shinichi Higashiue¹⁴, Shuzo Kobayashi¹⁴,
- 141 Hiroki Yamaguchi¹⁵, Yasunobu Nagata¹⁵, Satoshi Wakita¹⁵, Chikako Nito¹⁶, Yu-ki Iwasaki¹⁷,
- 342 Shigeo Murayama¹⁸, Kozo Yoshimori¹⁹, Yoshio Miki²⁰, Daisuke Obata²¹, Masahiko
- Higashiyama^{22} , Akihide Masumoto²³, Yoshinobu Koga²³ & Yukihiro Koretsune²⁴

344

- ^{1.} Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The
- 346 University of Tokyo, Tokyo, Japan.
- 347 \textdegree 2 Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The
- 348 University of Tokyo, Tokyo, Japan.
- 349 ³ The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- ⁴ Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo,

351 Tokyo, Japan.

- ⁵ Laboratory of Complex Trait Genomics, Graduate School of Frontier Sciences, The University 353 of Tokyo, Tokyo, Japan.
- ⁶ Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, 355 Japan.
- 356 ⁷ Division of Digital Genomics, Institute of Medical Science, The University of Tokyo, Tokyo, 357 Japan.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- ⁸ Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo,
- 359 Tokyo, Japan.
- ⁹ Department of Urology, Iwate Medical University, Iwate, Japan.
- ¹⁰ Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of
- 362 Medicine, Tokyo, Japan.
- ¹¹ Department of Respiratory Medicine, Juntendo University Graduate School of Medicine,
- 364 Tokyo, Japan.
- ¹² Division of Pharmacology, Department of Biomedical Science, Nihon University School of
- 366 Medicine, Tokyo, Japan.
- ¹³ Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon
- 368 University. School of Medicine, Tokyo, Japan.
- 369 ¹⁴ Tokushukai Group, Tokyo, Japan.
- ¹⁵ Department of Hematology, Nippon Medical School, Tokyo, Japan.
- ¹⁶ Laboratory for Clinical Research, Collaborative Research Center, Nippon Medical School,
- 372 Tokyo, Japan.
- ¹⁷ Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
- ¹⁸ Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
- ¹⁹375 Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
- ²⁰ The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- ²¹ Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science,
- 378 Shiga, Japan.
- ²² Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan.
- 380 ²³ Iizuka Hospital, Fukuoka, Japan.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

381 ²⁴ National Hospital Organization Osaka National Hospital, Osaka, Japan.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

References

- 1. Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, Backman JD, Bellomo TR,
- Bone WP, Biddinger KJ, Hui Q, Dikilitas O, Satterfield BA, Yang Y, Morley MP, Bradford Y,
- Burke M, Reza N, Charest B, Regeneron Genetics C, Judy RL, Puckelwartz MJ, Hakonarson H,
- Khan A, Kottyan LC, Kullo I, Luo Y, McNally EM, Rasmussen-Torvik LJ, Day SM, Do R,
- Phillips LS, Ellinor PT, Nadkarni GN, Ritchie MD, Arany Z, Cappola TP, Margulies KB,
- Aragam KG, Haggerty CM, Joseph J, Sun YV, Voight BF and Damrauer SM. Genome-wide
- association and multi-trait analyses characterize the common genetic architecture of heart failure.
- *Nat Commun*. 2022;13:6914.
- 2. Joseph J, Liu C, Hui Q, Aragam K, Wang Z, Charest B, Huffman JE, Keaton JM,
- Edwards TL, Demissie S, Djousse L, Casas JP, Gaziano JM, Cho K, Wilson PWF, Phillips LS,
- Program VAMV, O'Donnell CJ and Sun YV. Genetic architecture of heart failure with preserved

versus reduced ejection fraction. *Nat Commun*. 2022;13:7753.

- 3. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi SH, Shoemaker MB, Haas
- ME, Weng LC, Lindsay ME, Smith JG, Newton-Cheh C, Roden DM, London B, Investigators
- G, Wells QS, Ellinor PT, Kathiresan S, Lubitz SA and Genetic Risk Assessment of Defibrillator
- Events I. Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic
- Discovery. *Circulation*. 2019;139:489-501.
- 4. Pei YF, Liu YZ, Yang XL, Zhang H, Feng GJ, Wei XT and Zhang L. The genetic
- architecture of appendicular lean mass characterized by association analysis in the UK Biobank
- study. *Commun Biol*. 2020;3:608.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

5. Zhang L, Bartz TM, Santanasto A, Djousse L, Mukamal KJ, Forman DE, Hirsch CH,

- Newman AB, Gottdiener JS and Kizer JR. Body Composition and Incident Heart Failure in
- Older Adults: Results From 2 Prospective Cohorts. *J Am Heart Assoc*. 2022;11:e023707.
- 6. Gu Q, Yazdanpanah M, van Hoek M, Hofman A, Gao X, de Rooij FW and Sijbrands EJ.
- Common variants in PCSK1 influence blood pressure and body mass index. *J Hum Hypertens*.
- 2015;29:82-6.
- 7. Donertas HM, Fabian DK, Valenzuela MF, Partridge L and Thornton JM. Common
- genetic associations between age-related diseases. *Nat Aging*. 2021;1:400-412.
- 8. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki
- H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa
- K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K,
- Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda
- K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y and Komuro I. Population-
- specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci
- for coronary artery disease. *Nat Genet*. 2020;52:1169-1177.
- 9. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM,
- Tardaguila M, Huffman JE, Ritchie SC, Megy K, Ponstingl H, Penkett CJ, Albers PK, Wigdor
- EM, Sakaue S, Moscati A, Manansala R, Lo KS, Qian H, Akiyama M, Bartz TM, Ben-Shlomo
- Y, Beswick A, Bork-Jensen J, Bottinger EP, Brody JA, van Rooij FJA, Chitrala KN, Wilson
- PWF, Choquet H, Danesh J, Di Angelantonio E, Dimou N, Ding J, Elliott P, Esko T, Evans MK,
- Felix SB, Floyd JS, Broer L, Grarup N, Guo MH, Guo Q, Greinacher A, Haessler J, Hansen T,
- Howson JMM, Huang W, Jorgenson E, Kacprowski T, Kahonen M, Kamatani Y, Kanai M,
- Karthikeyan S, Koskeridis F, Lange LA, Lehtimaki T, Linneberg A, Liu Y, Lyytikainen LP,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Manichaikul A, Matsuda K, Mohlke KL, Mononen N, Murakami Y, Nadkarni GN, Nikus K,
- Pankratz N, Pedersen O, Preuss M, Psaty BM, Raitakari OT, Rich SS, Rodriguez BAT, Rosen
- JD, Rotter JI, Schubert P, Spracklen CN, Surendran P, Tang H, Tardif JC, Ghanbari M, Volker
- U, Volzke H, Watkins NA, Weiss S, Program VAMV, Cai N, Kundu K, Watt SB, Walter K,
- Zonderman AB, Cho K, Li Y, Loos RJF, Knight JC, Georges M, Stegle O, Evangelou E, Okada
- Y, Roberts DJ, Inouye M, Johnson AD, Auer PL, Astle WJ, Reiner AP, Butterworth AS,
- Ouwehand WH, Lettre G, Sankaran VG and Soranzo N. The Polygenic and Monogenic Basis of
- Blood Traits and Diseases. *Cell*. 2020;182:1214-1231 e11.
- 10. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H,
- Riveros-Mckay F, Kostadima MA, Lambourne JJ, Sivapalaratnam S, Downes K, Kundu K,
- Bomba L, Berentsen K, Bradley JR, Daugherty LC, Delaneau O, Freson K, Garner SF, Grassi L,
- Guerrero J, Haimel M, Janssen-Megens EM, Kaan A, Kamat M, Kim B, Mandoli A, Marchini J,
- Martens JHA, Meacham S, Megy K, O'Connell J, Petersen R, Sharifi N, Sheard SM, Staley JR,
- Tuna S, van der Ent M, Walter K, Wang SY, Wheeler E, Wilder SP, Iotchkova V, Moore C,
- Sambrook J, Stunnenberg HG, Di Angelantonio E, Kaptoge S, Kuijpers TW, Carrillo-de-Santa-
- Pau E, Juan D, Rico D, Valencia A, Chen L, Ge B, Vasquez L, Kwan T, Garrido-Martin D, Watt
- S, Yang Y, Guigo R, Beck S, Paul DS, Pastinen T, Bujold D, Bourque G, Frontini M, Danesh J,
- Roberts DJ, Ouwehand WH, Butterworth AS and Soranzo N. The Allelic Landscape of Human
- Blood Cell Trait Variation and Links to Common Complex Disease. *Cell*. 2016;167:1415-1429

e19.

- 11. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S, Loh
- PR, Lareau C, Shoresh N, Genovese G, Saunders A, Macosko E, Pollack S, Brainstorm C, Perry
- JRB, Buenrostro JD, Bernstein BE, Raychaudhuri S, McCarroll S, Neale BM and Price AL.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell
- types. *Nat Genet*. 2018;50:621-629.
- 12. Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, Ishigaki K, Terao C,
- Suzuki K, Akiyama M, Suita N, Masuda T, Ogawa K, Yamamoto K, Saeki Y, Matsushita M,
- Yoshimura M, Matsuoka H, Ikari K, Taniguchi A, Yamanaka H, Kawaji H, Lassmann T, Itoh M,
- Yoshitomi H, Ito H, Ohmura K, AR RF, Hayashizaki Y, Carninci P, Kumanogoh A, Kamatani
- Y, de Hoon M, Yamamoto K and Okada Y. Integration of genetics and miRNA-target gene
- network identified disease biology implicated in tissue specificity. *Nucleic Acids Res*.
- 2018;46:11898-11909.
- 13. Zhang MJ, Hou K, Dey KK, Sakaue S, Jagadeesh KA, Weinand K, Taychameekiatchai
- A, Rao P, Pisco AO, Zou J, Wang B, Gandal M, Raychaudhuri S, Pasaniuc B and Price AL.
- Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-
- seq data. *Nat Genet*. 2022;54:1572-1580.
- 14. de Leeuw CA, Mooij JM, Heskes T and Posthuma D. MAGMA: generalized gene-set
- analysis of GWAS data. *PLoS Comput Biol*. 2015;11:e1004219.